Benchmarking spleen tyrosine kinase (Syk) expression in T‐ and NK ‐cell neoplasms: Implications for therapeutic targeting

Documenti analoghi

• Safety and efficacy of spleen tyrosine kinase (Syk) inhibitors in the treatment of adults with persistent and chronic immune thrombocytopenia ( ITP ): A systematic review and meta‐analysis of randomised clinical trials
  di: Mus'ab Theeb Mustafa, et al.
  Pubblicazione: (2026)
• Epigenetic dysregulation and therapeutic targeting of RET receptor tyrosine kinase in high‐risk KMT2A ‐rearranged acute myeloid leukaemia
  di: Arundhati Chavan, et al.
  Pubblicazione: (2025)
• Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction
  di: Chenyu Lin, et al.
  Pubblicazione: (2024)
• Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure
  di: Mengyao Yuan, et al.
  Pubblicazione: (2025)
• Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients
  di: Vincent Alcazer, et al.
  Pubblicazione: (2024)